Management of Hyperglycemia in Patients with Chronic Kidney Disease

Introduction to eGFR-Based Treatment

The American Diabetes Association and the National Kidney Foundation recommend using metformin plus an SGLT2 inhibitor as first-line therapy for patients with eGFR ≥30 mL/min/1.73 m², with GLP-1 receptor agonists as the preferred third agent if needed 1, 2
For patients with eGFR <30 mL/min/1.73 m², metformin and SGLT2 inhibitors should be discontinued, and DPP-4 inhibitors, meglitinides, or short-acting sulfonylureas should be used with caution for hypoglycemia 1, 2, 3

For patients with eGFR ≥60, standard dosing of metformin (up to 2000 mg/day) can be used, while for those with eGFR 45-59, metformin should be initiated at half the standard dose 2
For patients with eGFR 30-44, metformin should be initiated at half dose and titrated to a maximum of half the standard dose (1000 mg/day) 2, 3
SGLT2 inhibitors should be added immediately to metformin for cardiovascular and kidney protection, independent of glucose lowering 1, 2, 4
GLP-1 receptor agonists are the preferred third agent due to their cardiovascular benefits, weight loss, and low hypoglycemia risk 1, 3, 4

DPP-4 inhibitors, such as linagliptin, can be used as an alternative to GLP-1 receptor agonists, with no dose adjustment needed at any eGFR 1, 4, 5
Meglitinides, such as repaglinide, can be used with caution, starting at 0.5 mg with meals if eGFR <30 5
Short-acting sulfonylureas, such as glipizide, can be used with extreme caution, starting at 2.5 mg daily, but glyburide should be avoided due to its active renally-cleared metabolites causing severe hypoglycemia 5, 3

Patients with eGFR <30 mL/min/1.73 m² have a 50% reduction in insulin requirements due to decreased renal insulin clearance, and sulfonylureas and meglitinides carry significant hypoglycemia risk 5, 3
eGFR should be monitored annually for patients with eGFR ≥60, every 3-6 months for those with eGFR 45-59, and more frequently for those with eGFR <30, especially with medication changes 2, 4
Volume status should be assessed for patients on SGLT2 inhibitors, particularly in those ≥65 years, due to the risk of volume depletion symptoms 2